Conversion therapy for gastric cancer (GC) has been the subject of much recent attention. It
is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors …

Background A pathologic complete response (pCR) can sometimes be induced by intensive
or long-term neoadjuvant chemotherapy (NAC). This prognostic research study based on a …

Background Neoadjuvant chemotherapy before radical gastrectomy is preferred for locally
advanced gastric cancer. To avoid the problematic use of pTNM for patients after …

Background Neoadjuvant chemotherapy (NAC) is a promising method of improving the
survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) …

Background Neoadjuvant therapy is recommended for locally advanced gastric cancer
patients (stage IB–IIIC). The objective of this study is to evaluate the accuracy of endoscopic …

It is well known that the decision-making on treating gastric cancer is usually the summary of
several experts' advice. Moreover, the interpretability and reliability of a model used to assist …

Background Pathologic complete response of a primary tumor (ypT0) after preoperative
therapy is associated with improved overall survival (OS). However, whether other variables …

Gastric cancer is one of the main causes of cancer-related deaths worldwide. Even when
diagnosed as a localized disease and resected with the intent to cure, recurrences …

The prognosis of stage IV gastric cancer (GC) is poor, with palliative chemotherapy
remaining the main therapeutic option. Studies increasingly indicate that patients with …

In the last 20 years, several clinical trials on neoadjuvant chemotherapy and chemo-
radiotherapy as a therapeutic approach for locally advanced gastric cancer have been …